Aurinia Pharmaceuticals Inc.
AUPH · XNASCIK 1600620fmd_1CG4R56E9KKQVV6AMPVR0Z0NQKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 34 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 50 | 46 | 134 | 176 | 235 | 283 |
| Cost of revenue | – | – | – | 0 | 0 | 1 | 6 | 14 | 28 | 33 |
| Gross profit | – | – | – | 0 | 50 | 45 | 128 | 161 | 207 | 250 |
| Research and development | 15 | 34 | 41 | 53 | 50 | 51 | 45 | 50 | 21 | 33 |
| Selling, general and administrative | – | – | – | 22 | 97 | 174 | 196 | 195 | – | – |
| Total operating expenses | – | – | 56 | 91 | 154 | – | – | 267 | 240 | 178 |
| Operating income | (25) | (47) | (55) | (91) | (104) | (181) | (111) | (92) | (5) | 105 |
| Interest expense | – | – | 0 | 0 | – | 0 | 0 | 3 | 5 | 4 |
| Interest and investment income | – | – | – | – | – | – | 5 | 17 | 17 | 14 |
| Income before taxes | – | (71) | (53) | (88) | (103) | (180) | (106) | (77) | 7 | 114 |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | 1 | 2 | 1 | 2 | (173) |
| Net income from continuing operations | – | (71) | (53) | (88) | (103) | (181) | (108) | (78) | 6 | 287 |
| Net income | (23) | (71) | (53) | (88) | (103) | (181) | (108) | (78) | 6 | 287 |